Plasma-derived Exosomal miR-25-3p and miR-23b-3p as Predictors of Response to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
- Zhao Jing 1, Zhen Guo 1, Chuanfeng Zhang 1
- Zhao Jing 1, Zhen Guo 1, Chuanfeng Zhang 1
- 1Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic of China.
- 0Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic of China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Exosomal miR-25-3p and miR-23b-3p show promise in predicting chemoradiotherapy response in esophageal cancer. MiR-25-3p also serves as a prognostic marker for progression-free survival in these patients.
Area Of Science
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background
- Exosomal microRNAs (miRNAs) are emerging as crucial biomarkers in oncology.
- The predictive role of exosomal miRNAs in esophageal squamous cell carcinoma (ESCC) response to chemoradiotherapy (CRT) remains largely unexplored.
Purpose Of The Study
- To investigate the potential of exosomal miRNAs as predictive biomarkers for CRT response in ESCC patients.
- To identify specific exosomal miRNAs that can differentiate responders from non-responders to CRT.
Main Methods
- Prospective enrollment of 40 ESCC patients undergoing CRT.
- Plasma exosome isolation using the EXODUS platform.
- Small RNA sequencing for miRNA discovery in responders vs. non-responders, followed by qRT-PCR validation in an extended cohort.
Main Results
- Five differentially expressed exosomal miRNAs were identified in the discovery phase.
- Exosomal miR-23b-3p and miR-25-3p demonstrated significant ability to distinguish responders from non-responders (AUCs 0.708 and 0.932, respectively).
- Low miR-25-3p levels correlated with shorter progression-free survival (PFS), and miR-25-3p was identified as an independent predictive biomarker for PFS.
Conclusions
- Exosomal miR-25-3p and miR-23b-3p are promising biomarkers for predicting early CRT effectiveness in locally advanced ESCC.
- Exosomal miR-25-3p represents a novel prognostic marker for ESCC.
- Larger prospective studies are warranted to confirm their clinical utility for personalized treatment decisions.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

